Nebenwirkungen · Exelon
Exelon 4.6 mg/24 h transdermal patch Exelon 9.5 mg/24 h transdermal patch Exelon 13.3 mg/24 h transdermal patch · Abschnitt 4.8 · PDF-Seite 42
HOS-087870 · Präparat HOS-083555
In two 24-week double-blind, placebo-controlled clinical trials, skin reactions were measured at each visit using a skin irritation rating scale. When observed in patients treated with Exelon transdermal patches, skin irritation was mostly slight or mild in severity. It was rated as severe in ≤2.2% of patients in these studies and in ≤3.7% of patients treated with Exelon transdermal patches in a Japanese study.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-24T11:34:00Z · SHA-256 de7d3796de42471f695291c0766fcf1a2fe650dc43b810dbff52cb58532f22d3 · Passage 3a46db0b9203f61529e44a1ce72781455a042b0fbc7f734530b83fa0d75e8359 · Zeichen 4638–5052 im Abschnitt